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a b s t r a c t
Since its peak in early 2016, the incidence of Zika virus (ZIKV) cases has declined to such low levels that
Phase 3 field efficacy trials may be infeasible. While great progress was made to rapidly advance several
vaccine candidates into Phase 1 and 2 clinical trials, in the absence of sustained viral transmission it may
be difficult to evaluate the effectiveness of ZIKV vaccine candidates by conducting traditional clinical dis-
ease endpoint efficacy studies. However, ZIKV is still circulating at low levels in some areas and is likely to
re-emerge in naïve populations or in sites of prior epidemics once population immunity wanes.
Therefore, the public health need for a ZIKV vaccine remains. To facilitate continued ZIKV vaccine devel-
opment efforts, the World Health Organization’s Initiative for Vaccine Research and the National
Institutes of Health’s National Institute of Allergy and Infectious Diseases co-hosted a meeting of experts
in March 2018 to identify strategies to demonstrate vaccine effectiveness in view of waning ZIKV disease
incidence. This paper outlines points for consideration for developers, regulators, and other stakeholders
working towards a licensed ZIKV vaccine. These deliberations may also be applicable to development of
vaccines for other emerging infections where the size, unpredictability, and ephemeral nature of out-
breaks makes clinical disease endpoint efficacy trials to demonstrate vaccine effectiveness infeasible.
 2019 Published by Elsevier Ltd.
1. Introduction
The World Health Organization (WHO) declared the cluster of
congenital microcephaly cases and other neurological disorders
reported in Brazil as a result of Zika virus (ZIKV) infection of preg-
nant mothers and their infants to be a Public Health Emergency of
International Concern (PHEIC) in February 2016. Just one month
later, external experts to WHO advised prioritizing the develop-
ment of a ZIKV vaccine, acknowledging that such development of
medical countermeasures remains imperative for a potential fur-
ther future outbreak [1]. The R&D communities responded rapidly,
with more than 40 vaccine candidates being initially evaluated in
pre-clinical studies and many progressing in further development.
Of these, several have advanced beyond pre-clinical studies in ani-
mals and entered Phase 1 clinical trials [2,3], with two candidates
having entered Phase 2 clinical trials [4,5]. Multiple vaccine plat-
forms have shown robust protection against ZIKV challenge in
mice and non-human primate (NHP) models. With a strong clinical
pipeline and promising results from animal studies, vaccine-
mediated prevention of ZIKV disease appears feasible.
While the peak of the epidemic occurred in the first quarter of
2016 when efforts to develop ZIKV vaccines were ramped up, the
number of cases in South America, the Caribbean, and Central
America dropped over the course of 2016, with very low transmis-
sion remaining in 2018 (Fig. 1). Most recently, just 2,550 cases of
Zika illness were reported to the Pan American Health Organiza-
tion (PAHO) in July 2018, compared to a peak of over 132,000 in
February 2016. These data are limited by incomplete country
reporting and incomplete laboratory confirmation. As a result of
the declining burden, in November 2016 WHO transitioned from
the PHEIC to a sustained program of activities around Zika [6].
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Despite the decline in cases, the development and licensure of a
ZIKV vaccine remains a critical global public health need. The U.S.
Centers for Disease Control and Prevention recently estimated
approximately one in seven infants born to mothers with labora-
tory evidence of ZIKV infection in pregnancy were diagnosed with
a Zika-associated birth defect, a neurodevelopmental abnormality
possibly associated with in utero ZIKV infection, or both [7]. Zika
continues to be on the 2018 list of WHO R&D Blueprint priority dis-
eases [8], and WHO recently published a ZIKV vaccine roadmap
with a vision for safe, effective and affordable ZIKV vaccines to pre-
vent congenital Zika syndrome (CZS) and other serious ZIKV-
associated clinical complications [3]. Low-level ZIKV transmission
remains in parts of Latin America. Even in the hardest hit areas,
over time herd immunity will wane thereby increasing the risk
of a future outbreak upon re-introduction of ZIKV. Further global
spread of Zika is likely given the increasing travel patterns
[9–11]. The epidemiology of ZIKV in Asia and Africa remains poorly
understood, where 2.6 billion people are estimated to live in areas
at risk for ZIKV [12].
Pre-licensure clinical evaluation of vaccines typically follows a
stepwise progression starting with early-stage clinical trials (e.g.,
Phase 1 and Phase 2) to obtain preliminary safety and immuno-
genicity data and information on dose and regimen of the vaccine
candidate. One or more pivotal Phase 3 trials is normally used to
demonstrate safety and efficacy [13]; pre-licensure clinical trials
are typically randomized and controlled and are conducted in areas
with sufficient disease transmission to estimate vaccine efficacy
against a clinical disease endpoint [14]. With low incidence of ZIKV
transmission and the unpredictable nature of future outbreaks and
consequent difficulty with future field trials, opportunities to con-
duct randomized-controlled clinical disease endpoint efficacy trials
of ZIKV vaccine candidates may be past. This presents challenges
for evaluation of efficacy of ZIKV vaccine candidates. In June
2017, WHO under its R&D Blueprint hosted an expert consultation
on efficacy trials of ZIKV vaccines, during which endpoints, trial
design, site selection for ZIKV vaccine efficacy trials were discussed
and recommendations made [15]. Since then, opportunities to con-
duct efficacy trials have further diminished.
To continue to facilitate ZIKV vaccine development efforts, the
WHO Initiative for Vaccine Research and the National Institutes of
Health (NIH), National Institute of Allergy and Infectious Diseases
(NIAID) co-hosted a meeting in March 2018 to discuss strategies to
demonstrate effectiveness of ZIKV vaccine candidates in the face of
waning and unpredictable disease burden. While recognizing the
importance of safety considerations, discussions at the meeting
were limited to approaches that could be used to demonstrate ZIKV
vaccine effectiveness outside of traditional field efficacy trials.WHO
and NIH share the goal of bringing one or more vaccine candidates
through late-stage clinical development and licensure so that a safe
and effective product is ready for use when needed. This paper out-
lines points for consideration for developers, regulators, and other
stakeholders working towards a licensed ZIKV vaccine (Box 1).
2. Challenges in ZIKV vaccine development
There are several challenges to ZIKV vaccine development that
influence evaluation strategies for ZIKV vaccines. These include
the need for well-characterized animal models relevant to human
disease; the potential role of pre-existing flavivirus immunity
impacting vaccine safety, immunogenicity, and/or clinical efficacy;
incomplete understanding of immune responses that would be
necessary to prevent fetal infection; the theoretical risk that vac-
cine immune responses could induce Guillain–Barré syndrome
(GBS); and challenges associated with vaccination of pregnant
women, potentially with a live vaccine or technologies based on
platforms not previously utilized in licensed human vaccines. Cur-
rent evidence suggests that even asymptomatic maternal infec-
tions with presumably low levels of viremia could result in CZS
[16], thereby setting the bar high with the potential need for ster-
ilizing immunity and robust T cell response to avert transplacental
transmission of ZIKV during pregnancy [17].
The ZIKV vaccine landscape has included more than 40 candi-
dates. Among them, nine are in early clinical development using
proven technologies like attenuation and inactivation, as well as
newer platforms for which no human vaccine has yet been
licensed, such as DNA and modified mRNA [2]. The most advanced
candidate, a DNA vaccine developed by NIAID, is currently under
evaluation in a Phase 2b clinical study in multiple sites and thus
may still be able to demonstrate clinical efficacy [4]. The trial is
designed to measure efficacy against ZIKV disease, with efficacy
against infection (symptomatic or asymptomatic) as a secondary
endpoint. If the vaccine candidate is efficacious, it is hoped that
immunological markers that predict protection [18] could be iden-
tified, which may also be useful in evaluation of other candidates.
3. Approaches to establish effectiveness in the absence of
clinical disease endpoint efficacy studies
Phase 1 and Phase 2 clinical studies will be needed to establish
initial safety and immunogenicity in a sufficient number of study
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Fig. 1. Monthly Zika illness case counts reported to the Pan American Health Organization (PAHO) during August 2015 to July 2018. Data courtesy of PAHO.
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participants before proceeding with the demonstration of vaccine
efficacy in support of licensure. In the case of vaccine candidates
for which traditional Phase 3 efficacy trials cannot be conducted
pre-licensure, alternative approaches need to be explored. It is con-
sidered likely that a data package that supports licensure will
include immunogenicity in animals and humans as well as animal
challenge studies. Developers are encouraged to meet early with
regulators to discuss the proposed data package and appropriate
regulatory pathways.
The approach to demonstrating vaccine efficacy differs depend-
ing on the regulatory pathway to licensure. In addition, available
regulatory pathways to licensure vary by country and regulatory
authority. For example, in the United States, a ZIKV vaccine could
be licensed by the US Food and Drug Administration (FDA) by
one of three available pathways: traditional approval, accelerated
approval, or the animal rule. A description of these pathways with
considerations specific to Zika has been published [19].
Similarly, the European Medicines Agency (EMA) has regulatory
tools and options to allow the licensure of a vaccine based on non-
traditional approaches when adequately justified. Approval under
exceptional circumstances and conditional marketing authoriza-
tion are among the regulatory pathways that could accommodate
for such scenarios. These pathways allow for flexibility in terms
of the overall evidence that would be required to support the effi-
cacy of the vaccine candidate and might include efficacy from
human challenge models or extrapolation of protection to humans
from adequate animal challenge models in which animals from a
relevant animal species recapitulating key aspects of human dis-
ease are protected after passive transfer of human antibodies
and/or after vaccination.
Regulatory pathways are available across national regulatory
agencies to advance vaccine candidates without the need for a tra-
ditional clinical disease endpoint efficacy trial to demonstrate vac-
cine efficacy and without the existence of a scientifically well-
established marker that predicts protection. In general, these path-
ways have in common initial licensure of a vaccine based on data
that include a non-clinical endpoint in human studies and a
requirement for post-licensure studies to further define or confirm
benefit. For example, the US FDA Accelerated Approval regulation
permits use of a surrogate marker (e.g., an immune response rea-
sonably likely to predict the benefit of the product) or an interme-
diate clinical endpoint to demonstrate vaccine efficacy in support
of licensure. For vaccines, this surrogate marker is usually an
immunological endpoint measured in an in vitro assay. Assays that
might be able to predict a reasonable likelihood of clinical benefit
could be based on ZIKV challenge studies in mice that received pas-
sively transferred human immune serum (harvested post-
vaccination). Immune markers associated with protection in ani-
mal studies and/or field efficacy studies (should incidence permit)
could also be considered. The extent to which an immune marker
associated with protection for a given vaccine candidate could pre-
dict efficacy of other vaccine candidates, particularly those
employing differing vaccine platforms, is unknown at present.
For some vaccines where the mechanism of protection is well
understood, the immune marker that predicts protection is
platform-independent (e.g., the protective immune response for
Japanese encephalitis vaccines is relevant for both the live attenu-
ated, live recombinant (chimeric), and inactivated vaccines) [18];
however, it is possible that it could be vaccine specific, depending
on characteristics such as candidate antigen and method of deliv-
ery [19].
There are also different options for an appropriate clinical mar-
ker or intermediate endpoint that could be used as an endpoint in
animal challenge studies and extrapolated to humans. One end-
point to be considered is protection against ZIKV viremia post-
challenge. However, prevention of in utero infection in an animal
pregnancy model (or in a combination of models) or demonstra-
tion of sterilizing immunity (defined by the lack of a serologic
immune response, e.g., <4-fold increase in neutralizing antibody
titers post-challenge) may also be useful endpoints, as they indi-
cate more direct benefit even though they may be more difficult
to attain. Feasibility of individual endpoints may also depend on
the timing of challenge relative to vaccination: sterilizing immu-
nity may be achievable four weeks after vaccination but may be
more difficult to attain 12 months after vaccination.
4. Immune markers reasonably likely to predict clinical benefit
From a regulatory perspective, it will be useful to identify an
immune marker that is reasonably likely to predict clinical benefit
[18]. Such markers based on neutralizing antibodies (as measured
by the Plaque Reduction Neutralization Test, or PRNT) have been
defined for several flavivirus vaccines: titers of 10 are accepted
as protective for Japanese encephalitis and Tick-borne encephalitis
vaccines, while a titer as low as 5 has been proposed for Yellow
fever vaccine [18]. For dengue, no neutralizing antibody titer has
been identified, although in large Phase 3 clinical trials higher neu-
tralizing antibody titers were associated with reduced likelihood of
disease [20]. Thus, neutralizing antibody has potential as an
immune endpoint to predict benefit for ZIKV vaccines.
However, while promising data exist, there are information
gaps regarding potential use of neutralizing antibodies to predict
clinical benefit of ZIKV vaccines. While relatively low titers are
accepted as predictive of protection for vaccines against several
other flaviviruses, the titer needed to protect against ZIKV may
be different from other flaviviruses. Furthermore, it is unknown
whether the titer required to protect against clinical disease in
the vaccinee is the same as that required to protect against fetal
infection. Preliminary data from NIH found that in vitro neutraliz-
ing antibodies of similar titers induced by two related DNA vaccine
candidates were associated with different levels of protection
against viremia in animal challenge studies [unpublished data].
This finding suggests that other characteristics of the neutralizing
antibody (besides the titer) may need to be identified in order to
predict protection across vaccine candidates. Systems vaccinology
approaches have been successful in characterizing complex
immune functions associated with vaccine protection for other
viruses, e.g., HIV, and may have applicability to ZIKV [21].
Finally, concerns have been raised about using neutralization
assays to measure ZIKV vaccine immunogenicity in individuals
who have been previously exposed to other flaviviruses, either
through natural infection or vaccination, due to potential cross-
reactivity [22]. However, in recent longitudinal studies, patterns
of antibody cross-neutralization in primary and secondary DENV
infections suggest that ZIKV lies outside the DENV serocomplex
[23]. Neutralizing antibody titers to ZIKV were markedly lower
than to the infecting DENV and heterologous DENV serotypes.
Cross-neutralization was greatest in early convalescence, then
ZIKV neutralization titers decreased, remaining at low levels over
time. Neutralizing antibody titers can therefore distinguish ZIKV
from DENV infections during late convalescence when all viruses
are analyzed simultaneously.
The assay used to measure neutralizing antibody will affect the
reported numerical titer, and careful interpretation in view of the
cell type used for assay, virus strain, and assay type is needed. Pri-
mary assays being used for ZIKV vaccine candidates include the
traditional PRNT, microneutralization test (MN), and reporter virus
particle assays. These three assays differ with respect to how viral
infection is enumerated in the presence or absence of antibody,
adaptability to multiple cellular substrates, and requirement for
viral replication. Standardized, validated neutralization assays
K.S. Vannice et al. / Vaccine 37 (2019) 863–868 865
could help facilitate vaccine development. Several efforts are
underway to support assay validation.
The National Institute for Biological Standards and Control
(NIBSC) is currently in the process of validating a serology standard
and a PCR standard that will be reviewed by the WHO Expert Com-
mittee on Biologicals Standardization (ECBS). WHO international
standards and reference materials for designating the activity of
vaccines and other biologicals can serve as a basis for evaluation
of the quality, safety and efficacy of these products for the purpose
of licensure as well as post-licensure. These standards can support
WHO prequalification and they also allow comparability of data
worldwide [24]. They are developed through the international col-
laborative laboratory studies and serve as the primary calibrants
against which national measurement standards or working stan-
dards are benchmarked. In October 2018 the ECBS reviewed the
outcomes of the collaborative study conducted by the NIBSC and
adopted the 1st International Standard as Anti-Asian lineage ZIKV
antibody (human) with the assigned unitage of 250 International
Units per ampoule [25]. This standard could be utilized for diagno-
sis, vaccine evaluation and sero-surveillance.
NIH, through its contracting partners, is working to produce and
characterize master and working ZIKV stocks, generate critical
reagents, and develop and standardize assays. Assay development
and optimization, and ultimately qualification, is underway or
planned for the plaque assay, RT-qPCR, Reporter viral particles-
flow neutralization (RVP-FN) assay, MN assay, and PRNT. Standard-
ized protocols and qualified assays for human clinical trials,
bridged to use in NHP challenge studies, will be made available
to developers.
5. Results from animal challenge studies
Animal models are an important element supporting licensure
of vaccines in case human efficacy studies are not feasible. Mouse
challenge models to evaluate efficacy can be useful tools for com-
paring different candidates and to study vaccine modes of action.
NHP challenge models may more closely predict human outcomes
and are suitable to explore efficacy against various disease end-
points, potentially including protection against CZS, transplacental
infection, GBS, and viral persistence. Passive transfer studies in
which human immune sera (generated in response to infection
or vaccination) is transferred into animals, which are subsequently
challenged with ZIKV, may be the closest currently feasible
approximation in animal studies to demonstrate the protective
value of human antibodies and to infer clinical benefit in humans.
Several animal models for ZIKV infection and disease are cur-
rently being used. Murine models include immunocompetent
adult, immunocompromised adult, and immunocompetent neona-
tal mice. NHP challenge models have been developed using rhesus
macaques, cynomolgus macaques, and pigtail macaques. Guinea
pig [26] and chicken embryo models [27] are also under develop-
ment. Small and large animal models that could potentially be
used to study vaccine effects on outcomes of ZIKV infection in
pregnancy are also becoming available (e.g., [28–30]).
Vaccine data from animal challenge studies have been promis-
ing. The endpoint in most animal vaccine challenge studies is pro-
tection against viremia, measured as a lack of anamnestic response
post challenge and/or lack of viremia post-challenge. Several vac-
cine candidates have demonstrated apparent sterilizing immunity
when challenged one month following vaccination. Candidates
have been successfully evaluated in NHPs with challenge one year
post-vaccination [31]. In several studies with mice and NHPs, a
neutralizing antibody titer of approximately 100 as measured by
the MN assay was associated with protection against viremia with
ZIKV challenge, while neutralizing titers lower than this were typ-
ically not protective (e.g., [32–35]). This same titer was also effec-
tive in passive transfer of human immune sera obtained from study
participants in Phase 1 vaccine clinical trials into mice prior to
challenge [34]. Additionally, depleting CD4 + and CD8 + T lympho-
cytes cells did not affect vaccine protection in these mouse studies
[36]. Thus, passive protection studies in mouse and NHP models
support strong consideration of neutralizing antibody as a measure
of immune responses likely associated with protection [32,34].
Challenge models to test vaccine candidates for their ability to
impact pregnancy outcomes may identify titer levels sufficient to
protect against CZS. Preliminary findings from challenge studies
in vaccinated mice indicate markedly diminished levels of ZIKV
RNA in maternal, placental, and fetal tissues, which resulted in pro-
tection against placental damage and fetal demise [37]. While
these findings should always be contextualized in view of potential
interspecies differences, they support the proof-of-concept that
protection against CZS is possible.
6. Controlled human infection model for Zika
Controlled Human Infection Model (CHIM) studies have been
developed for several diseases, including influenza, malaria, cho-
lera, and dengue [38]. The US FDA recently licensed a cholera vac-
cine on the basis of efficacy from CHIM and supportive safety and
immunogenicity trials [39]. Thus, CHIM could be considered to sup-
port vaccine licensure, particularly in situations when randomized
controlled field studies with a clinical disease endpoint are infeasi-
ble. WHO has summarized regulatory considerations for human
challenge trials conducted as part of vaccine development [40].
CHIMs have been utilized to enhance vaccine development in
several ways: (1) to assist with down-selecting vaccine candidates;
(2) to study disease pathogenesis; (3) to directly evaluate vaccine
efficacy and duration of protection, and (4) to identify immune
markers that can predict protection. Based on these considerations,
the role of a ZIKV CHIM for vaccine development has been dis-
cussed [26].
A December 2016 NIAID and the Walter Reed Army Institute of
Research (WRAIR)-cosponsored expert consultation discussed con-
ditions under which use of a ZIKV CHIM could be ethically justified.
Participants raised concern that a CHIM may not be justified if tra-
ditional field efficacy trials were considered feasible, and that a
ZIKV CHIM study may present risks to non-participants (third par-
ties) if the challenge strain spread to individuals not enrolled in the
study [41]. The latter could be mitigated through careful study
design if the length of time of ZIKV transmission after infection
was better characterized; and at the time of the report, incidence
of ZIKV infection was felt to be high enough that field efficacy trials
appeared feasible. Therefore, members of the expert committee
felt that the social value of CHIM, when combined with other
uncertainties, did not justify the potential risks of performing the
studies at that time.
Fifteen months later, the calculus has changed. Traditional effi-
cacy trials may be very difficult, if not infeasible, to conduct and
the ability to directly demonstrate efficacy in a CHIM could provide
the data needed for licensure. Data suggest that from ZIKV-infected
individuals with low levels of viremia, ZIKV is only transmissible
for 30 days [42]. Several strategies have been proposed that could
greatly mitigate the risk to bystanders that are not participating in
the study (such as sexual partners or fetuses), such as only enrol-
ling females not of child-bearing age or mandating use of highly
effective contraception [43]. If certain populations were not
included in CHIM, immunobridging with an accepted immune
marker could support potential use of vaccine in these populations.
The data package and CHIM results, along with supportive safety
and immunogenicity studies would determine the indication,
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which is generally based on the vaccine tested and what was
demonstrated.
Thus, it is perceived that the situation with respect to consider-
ation of ZIKV CHIM has changed substantially since the time of the
ethics consultation in 2016, with greater appreciation for societal
value and also better or improved understanding of how risksmight
be mitigated. Meeting participants, including representatives of
regulatory agencies US FDA and EMA, agreed that CHIMmay repre-
sent a useful tool for evaluating ZIKV vaccine candidates. Scientific
issues for CHIMs, including the challenge strain, route of adminis-
tration, dose, and timing of challenge post-vaccination will need
to be addressed before CHIMs are used to evaluate vaccine efficacy.
7. Post-licensure studies
Regardless of the regulatory pathway used to demonstrate vac-
cine effectiveness for the purposes of regulatory approval, post-
marketing studies will be needed for approved ZIKV vaccines.
Depending on the licensure pathway, post-licensure studies may
be required as confirmatory effectiveness and expanded safety
studies, but even if not required by applicable regulation, it will
be important to assess vaccine impact on the serious but rare
sequelae of ZIKV infection.
In addition to virologically-confirmed Zika disease, likely effec-
tiveness outcomes of interest for post-licensure studies include
vaccine effectiveness against CZS and GBS, which are too rare in
occurrence to serve as clinical endpoints in pre-licensure trials.
Such studies are likely to be challenging in the context of a ZIKV
outbreak in affected areas. The majority of ZIKV-associated CZS
occurred in areas of Brazil with limited surveillance and research
infrastructure. The ability to do post-licensure studies also requires
vaccine rollout on a large basis, as the utility of these studies in
gaining additional information on the vaccine may be limited if
small select populations are vaccinated. In order to be successful,
it is critical to know the vaccination status of individuals, which
(depending on study design) may require a vaccine registry, and
for CZS it will be important to be able to link fetal outcomes with
maternal immunization status. Such infrastructure is lacking in
many parts of theworld, especially for capturing adult vaccinations.
Advanced preparation is therefore critical to assure the success
of complex post-licensure studies. In Latin America, local ZIKV epi-
demics lasted at times only a few months, which is too short a time
to set up a vaccination program and post-licensure study once an
outbreak has emerged. Protocols should be prepared, and regula-
tory and ethics approvals received, in advance.
Several post-licensure study designs could be considered,
including cohort and test-negative case-control designs. Because
CZS presents with a wide range of clinical manifestations, interme-
diate markers of CZS that are routinely collected for all neonates,
such as head circumference, birth weight, and gestational age, will
likely need to be used as part of a case definition of CZS. Heel blood
samples that are collected for metabolic screening could poten-
tially be used to test for ZIKV antibodies. Ongoing projects, such
as the WHO individual participant data-meta-analysis (IPD-MA)
that will combine de-identified data on individual pregnant
women from different cohorts in Latin America, will help to iden-
tify the key predictors of CZS that could be used as a pragmatic
endpoint in a vaccine effectiveness post-licensure study [44]. A
substantial investment in post-licensure studies will be needed.
8. Conclusions
Tremendous progress has been made in ZIKV vaccine develop-
ment since the WHO declaration of PHEIC in February 2016. Data
available from pre-clinical animal studies to date show that vac-
cine candidates are capable of protecting animals from subsequent
challenge with ZIKV. There are several regulatory pathways for
ZIKV vaccine candidate licensure if field clinical disease endpoint
efficacy studies are no longer feasible in the context of a waning
epidemic. Several regulatory authorities have the ability to
approve vaccines when there is a reasonable likelihood of clinical
benefit, allowing considerable regulatory flexibility. Based on
experiences with other flavivirus vaccines, identifying immune
markers associated with protection are likely feasible, but post-
licensure studies would be needed to confirm clinical benefit.
CHIM studies may now present the most direct opportunity to
demonstrate ZIKV vaccine candidate efficacy. Manufacturers are
encouraged to meet with regulators as early as possible to discuss
options for regulatory pathways and post-licensure studies. While
data packages without field efficacy trials may be sufficient for ini-
tial licensure, policy makers will also need data to inform decision-
making for vaccine introduction. Post-licensure data might be
required by regulators and would be relevant to inform and expe-
dite public health decisions on vaccine use. Public health research
agendas are critical to support aspects of vaccine development
such as clinical trial site selection, and aspects following licensure,
such as post-licensure studies and ZIKV transmission globally.
Box 1 Points for consideration to advance ZIKV vaccine candi-
dates during a waning epidemic.
 Heterogeneity of incidence of ZIKV infection in time and
space is one of the key challenges for ZIKV vaccine clinical
trial design.
 Neutralizing antibodies are likely to be an important
immune marker of protection; however, a broader assess-
ment of the immune response is encouraged.
 Availability of WHO standards, standardization and valida-
tion of assays are critical for appropriate assessment of
the immune response to Zika vaccine as well as for the
interpretation of the results.
 Passive transfer studies in animals demonstrating protec-
tion against disease, infection, and CZS with human sera
may provide a useful approximation of clinical benefit in
humans in the absence of traditional efficacy trials.
 Traditional clinical disease endpoint efficacy studies may
be challenging or even infeasible given the current epi-
demiology of ZIKV; thus, the societal benefit for CHIM is
evident. With proper communications plans, risk mitiga-
tion in place, and ethical review, ZIKV CHIM could be valu-
able for moving forward with ZIKV vaccine development
and licensure.
 Post-licensure studies will be required for all approved
ZIKV vaccines: the specific studies will depend on the reg-
ulatory pathway, the indication, and vaccine
characteristics.
 Many data gaps remain, and further epidemiologic
research is critical to inform optimal vaccine development
and use.
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